Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYH9087
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
SYH9087 is a long-acting, once-weekly subcutaneous injection of rotigotine, a non-ergoline dopamine receptor agonist, being developed by CSPC Pharmaceutical Group for the treatment of Parkinson's disease. Utilizing CSPC's proprietary long-acting delivery technology platform, the formulation is based on biocompatible excipients that form an in-situ drug depot upon subcutaneous injection, enabling sustained and continuous release of rotigotine over a week. Compared to existing intramuscular rotigotine microsphere formulations, SYH9087 is administered subcutaneously, requires no complex reconstitution prior to clinical use, and utilizes a finer-gauge needle with a smaller injection volume, which is expected to reduce injection-site pain and improve patient compliance. In September 2026, the National Medical Products Administration (NMPA) of China approved clinical trials for SYH9087.
- Other names
- rotigotine long-acting injection
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on SYH9087.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYH9087.